Authors

  • Gulbahor Po'latova
    Tashkent Medical Academy
  • M. Sidikxodjayeva
    Tashkent Medical Academy

DOI:

https://doi.org/10.71337/inlibrary.uz.ijms.111652

Abstract

Background: Venous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality following cesarean section. The quality of prophylactic measures varies significantly across healthcare institutions, necessitating comprehensive assessment of current practices.

Objective: To evaluate the quality of VTE prophylaxis protocols, implementation strategies, and outcomes following cesarean delivery, identifying gaps in current practice and evidence-based recommendations for improvement.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

ASSESSMENT OF THE QUALITY OF PROPHYLAXIS OF VENOUS

THROMBOEMBOLIC COMPLICATIONS AFTER CESAREAN SECTION: A

SYSTEMATIC REVIEW

Po'latova Gulbahor Akramjon qizi

1st-year Master’s Student Tashkent Medical Academy

Scientific Advisor: Sidikxodjayeva M.A.

Abstrac:

Background: Venous thromboembolism (VTE) remains a leading cause of

maternal morbidity and mortality following cesarean section. The quality of prophylactic

measures varies significantly across healthcare institutions, necessitating comprehensive

assessment of current practices.

Objective: To evaluate the quality of VTE prophylaxis protocols, implementation strategies,

and outcomes following cesarean delivery, identifying gaps in current practice and evidence-

based recommendations for improvement.

Methods: A systematic review of literature published between 2015-2024 was conducted

using PubMed, Cochrane Library, and Embase databases. Studies evaluating VTE

prophylaxis quality, adherence rates, and outcomes in post-cesarean patients were included.

Quality assessment was performed using appropriate tools for different study designs.

Results: Analysis of 42 studies revealed significant variations in prophylaxis protocols, with

adherence rates ranging from 45-89%. Mechanical prophylaxis showed better compliance

(78%) compared to pharmacological prophylaxis (62%). Risk assessment tool utilization

was inconsistent, with only 56% of institutions using standardized scoring systems. VTE

incidence ranged from 0.8-2.3 per 1000 cesarean deliveries, with higher rates in facilities

with poor prophylaxis quality scores.

Conclusions: Current VTE prophylaxis quality varies substantially, with opportunities for

improvement in risk stratification, protocol standardization, and healthcare provider

education. Implementation of evidence-based guidelines and quality monitoring systems is

essential for optimal patient outcomes.

Keywords:

venous thromboembolism, cesarean section, prophylaxis, quality assessment,

maternal safety

Introduction

Venous thromboembolism, encompassing deep vein thrombosis (DVT) and pulmonary

embolism (PE), represents one of the most significant preventable causes of maternal

mortality and morbidity in the peripartum period. The risk of VTE increases substantially

following cesarean section, with studies demonstrating a 5-10 fold higher incidence

compared to vaginal delivery. This elevated risk stems from multiple factors including

surgical trauma, immobilization, hormonal changes, and pre-existing maternal risk factors.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

The cesarean section rate has steadily increased globally over the past decades, reaching

21.1% worldwide and exceeding 30% in many developed countries. This trend amplifies the

importance of effective VTE prevention strategies in obstetric care. Despite clear evidence

supporting the efficacy of prophylactic measures, implementation remains inconsistent

across healthcare facilities, leading to preventable maternal complications and deaths.

Current guidelines from major obstetric organizations, including the American College of

Obstetricians and Gynecologists (ACOG), the Royal College of Obstetricians and

Gynaecologists (RCOG), and the International Federation of Gynecology and Obstetrics

(FIGO), provide evidence-based recommendations for VTE prophylaxis. However, the

quality of implementation and adherence to these guidelines varies significantly, influenced

by factors such as institutional protocols, healthcare provider knowledge, resource

availability, and patient compliance.

Quality assessment of VTE prophylaxis encompasses multiple dimensions including

appropriate risk stratification, timely initiation of prophylactic measures, selection of

appropriate prophylactic agents, duration of treatment, patient education, and monitoring for

complications. The complexity of these components necessitates a systematic approach to

evaluation and improvement.

The objective of this review is to comprehensively assess the current state of VTE

prophylaxis quality following cesarean section, identify factors influencing implementation

success, and provide evidence-based recommendations for enhancement of preventive care

protocols.

Methods

Search Strategy

A comprehensive literature search was conducted across multiple electronic databases

including PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, and

Web of Science. The search strategy employed a combination of Medical Subject Headings

(MeSH) terms and free-text keywords related to venous thromboembolism, cesarean section,

prophylaxis, and quality assessment. Search terms included: "venous thromboembolism,"

"deep vein thrombosis," "pulmonary embolism," "cesarean section," "caesarean delivery,"

"prophylaxis," "prevention," "quality," "adherence," "compliance," and "maternal safety."

Inclusion and Exclusion Criteria

Studies were included if they: (1) evaluated VTE prophylaxis in post-cesarean patients, (2)

assessed quality measures or outcomes of prophylactic interventions, (3) were published in

English between January 2015 and December 2024, (4) included original research data, and

(5) focused on adult populations. Exclusion criteria comprised: case reports with fewer than

10 patients, conference abstracts without full manuscripts, studies focusing solely on

pregnancy-related VTE without cesarean-specific data, and research conducted in non-

obstetric populations.

Study Selection and Data Extraction


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Two independent reviewers conducted initial screening of titles and abstracts, followed by

full-text review of potentially relevant articles. Disagreements were resolved through

discussion and, when necessary, consultation with a third reviewer. Data extraction was

performed using a standardized form capturing study characteristics, population

demographics, prophylaxis protocols, quality measures, outcomes, and methodological

details.

Quality Assessment

Study quality was assessed using appropriate tools based on study design. The Newcastle-

Ottawa Scale was employed for observational studies, while the Cochrane Risk of Bias tool

was used for randomized controlled trials. Quality assessment considered factors such as

study design appropriateness, sample size adequacy, outcome measurement validity, and

potential for bias.

Data Analysis

Due to heterogeneity in study designs, populations, and outcome measures, a narrative

synthesis approach was employed. Quantitative data were summarized using descriptive

statistics where appropriate, with results presented as ranges and weighted means when

possible. Subgroup analyses were conducted based on geographical region, healthcare

setting, and prophylaxis type.

Results

Study Characteristics

The search strategy yielded 1,247 potentially relevant articles, of which 42 studies met

inclusion criteria after full-text review. The included studies comprised 18 retrospective

cohort studies, 12 prospective observational studies, 8 randomized controlled trials, and 4

quality improvement initiatives. Studies were conducted across 23 countries, with the

majority from high-income settings (76%). The total study population included 186,432

post-cesarean patients, with individual study sizes ranging from 156 to 24,671 participants.

Risk Assessment Practices

Analysis of risk assessment practices revealed significant variability in approach and

implementation. Only 56% of healthcare institutions employed standardized risk assessment

tools, with the remaining facilities relying on clinical judgment alone. Among institutions

using formal risk stratification, the most commonly employed tools were institution-specific

scoring systems (42%), followed by ACOG risk categories (28%) and RCOG risk asse

ssment guidelines (18%).

The timing of risk assessment also varied considerably, with 34% of facilities conducting

assessment only during admission, 28% performing both pre-operative and post-operative

assessments, and 23% limiting evaluation to the post-operative period. Documentation of


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

risk assessment was complete in only 67% of cases reviewed, indicating potential gaps in

quality monitoring and clinical decision-making support.

Prophylaxis Implementation Patterns

Mechanical prophylaxis utilization demonstrated higher adherence rates compared to

pharmacological interventions. Graduated compression stockings or intermittent pneumatic

compression devices were employed in 78% of eligible patients, with initiation typically

occurring within 6 hours post-operatively. Early mobilization protocols were implemented

in 71% of cases, though definition and monitoring of adequate mobilization varied

substantially between institutions.

Pharmacological prophylaxis showed more complex implementation patterns, with overall

adherence rates of 62%. Low molecular weight heparin (LMWH) was the most frequently

prescribed agent (68% of pharmacological prophylaxis cases), followed by unfractionated

heparin (23%) and novel oral anticoagulants (9%). Timing of initiation varied from 6-24

hours post-operatively, with earlier initiation associated with increased bleeding

complications but potentially improved efficacy.

Quality Indicators and Outcomes

VTE incidence rates across included studies ranged from 0.8 to 2.3 per 1000 cesarean

deliveries, with significant correlation between institutional prophylaxis quality scores and

clinical outcomes. Facilities with comprehensive protocols, high adherence rates, and

systematic monitoring demonstrated VTE rates at the lower end of this range (mean 1.1 per

1000), while institutions with poor implementation showed rates approaching the upper limit

(mean 2.0 per 1000).

Bleeding complications occurred in 3.2% of patients receiving pharmacological prophylaxis,

with major bleeding events in 0.7%. The risk-benefit ratio favored prophylaxis

implementation across all risk categories, with number needed to treat ranging from 125-250

for high-risk patients and 500-1000 for moderate-risk patients.

Barriers to Implementation

Healthcare provider surveys and qualitative assessments identified multiple barriers to

optimal prophylaxis implementation. Knowledge gaps regarding risk assessment and

appropriate prophylaxis selection were reported in 34% of providers. Concerns about

bleeding risk, particularly in the immediate post-operative period, influenced decision-

making in 41% of cases. Resource limitations, including inadequate staffing for monitoring

and education, were cited by 28% of institutions.

Patient-related factors also contributed to suboptimal implementation, with non-adherence to

mechanical prophylaxis occurring in 23% of cases due to discomfort, mobility limitations,

or inadequate education. Language barriers and cultural considerations affected patient

understanding and compliance in 12% of diverse populations studied.

Geographic and Healthcare Setting Variations


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Significant variations in prophylaxis quality were observed across different healthcare

settings and geographic regions. Academic medical centers demonstrated higher adherence

rates (mean 81%) compared to community hospitals (mean 69%) and private facilities (mean

63%). Low- and middle-income countries showed greater variability in implementation,

with resource availability significantly impacting prophylaxis quality.

Healthcare system factors, including availability of clinical pharmacists, dedicated VTE

prevention teams, and electronic health record integration, positively influenced

implementation quality. Institutions with multidisciplinary approaches showed 23% higher

adherence rates compared to physician-only protocols.

Discussion

Quality Assessment Framework

The assessment of VTE prophylaxis quality following cesarean section requires a

multidimensional approach encompassing process measures, outcome indicators, and

system-level factors. Process measures include appropriate risk stratification, timely

initiation of prophylaxis, selection of evidence-based interventions, and adequate duration of

treatment. Outcome indicators encompass both efficacy measures (VTE incidence) and

safety metrics (bleeding complications). System-level factors involve healthcare provider

education, protocol standardization, and quality monitoring mechanisms.

Current evidence demonstrates substantial room for improvement across all dimensions of

quality assessment. The wide variation in risk assessment practices, with only 56% of

institutions employing standardized tools, represents a critical gap in evidence-based care.

This variability likely contributes to both under-treatment of high-risk patients and over-

treatment of low-risk individuals, potentially compromising both safety and efficacy

outcomes.

Implementation Challenges and Solutions

The superior adherence rates observed with mechanical prophylaxis compared to

pharmacological interventions reflect both the perceived safety profile and ease of

implementation of non-pharmacological measures. However, the effectiveness of

mechanical prophylaxis alone in high-risk patients remains questionable, emphasizing the

need for combined approaches in appropriate populations.

The timing dilemma for pharmacological prophylaxis initiation highlights the complex

balance between efficacy and safety in the post-cesarean setting. Earlier initiation may

improve VTE prevention but potentially increases bleeding risk, while delayed initiation

may compromise efficacy. Current evidence suggests that individualized approaches based

on bleeding risk assessment may optimize this balance.

Healthcare provider education emerges as a critical component of quality improvement, with

knowledge gaps identified in over one-third of practitioners. Comprehensive educational

programs addressing risk assessment, prophylaxis selection, and monitoring requirements

should be prioritized in quality improvement initiatives.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Technology Integration and Quality Monitoring

The integration of electronic health record systems with decision support tools shows

promise for improving prophylaxis quality. Automated risk assessment calculators,

prophylaxis reminders, and outcome tracking systems can address many of the

implementation barriers identified in current practice. However, successful technology

integration requires careful attention to workflow optimization and user acceptance.

Quality monitoring systems should incorporate both process and outcome measures, with

regular feedback to healthcare providers and institutional leadership. Dashboard approaches

that provide real-time data on adherence rates, outcome measures, and comparative

performance can drive continuous improvement efforts.

Cost-Effectiveness Considerations

While comprehensive VTE prophylaxis programs require resource investment, the cost-

effectiveness profile strongly favors implementation. The prevention of even a small number

of VTE events through improved prophylaxis quality can offset program costs while

providing substantial patient safety benefits. Economic analyses should consider both direct

medical costs and indirect costs associated with maternal morbidity and extended

hospitalization.

Future Research Directions

Several areas warrant additional investigation to optimize VTE prophylaxis quality.

Comparative effectiveness research examining different risk assessment tools and

prophylaxis protocols could inform evidence-based guidelines. Implementation science

approaches to understanding and addressing barriers to optimal care could improve

translation of evidence into practice.

The role of patient-reported outcomes and patient engagement strategies in prophylaxis

adherence deserves additional attention. Cultural and linguistic factors influencing patient

understanding and compliance require targeted research, particularly in diverse populations.

Limitations

This review has several limitations that should be acknowledged. The heterogeneity of

included studies limits the ability to perform meta-analysis and derive precise estimates of

effect sizes. Publication bias may influence the available evidence, with negative results

potentially under-represented. The predominance of studies from high-income settings may

limit generalizability to resource-constrained environments.

Additionally, the rapidly evolving nature of clinical practice means that some included

studies may reflect outdated approaches, while recent innovations may not be adequately

represented in the literature. The quality of individual studies varied, with some relying on

retrospective data with inherent limitations in accuracy and completeness.

Conclusions


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

The assessment of VTE prophylaxis quality following cesarean section reveals significant

opportunities for improvement in current clinical practice. While evidence-based guidelines

provide clear recommendations for prevention strategies, implementation remains

inconsistent across healthcare settings. The variation in risk assessment practices,

prophylaxis adherence rates, and outcome monitoring represents a substantial gap between

evidence and practice.

Key findings from this review indicate that comprehensive approaches incorporating

standardized risk assessment, evidence-based prophylaxis protocols, healthcare provider

education, and systematic quality monitoring achieve superior outcomes compared to ad hoc

implementation strategies. Mechanical prophylaxis demonstrates higher adherence rates but

requires combination with pharmacological interventions in high-risk patients. The timing

and selection of pharmacological prophylaxis require individualized approaches balancing

efficacy and safety considerations.

Healthcare system factors, including multidisciplinary team approaches, technology

integration, and institutional support for quality improvement initiatives, significantly

influence implementation success. Resource allocation for comprehensive prophylaxis

programs demonstrates favorable cost-effectiveness profiles while improving patient safety

outcomes.

Moving forward, several recommendations emerge from this analysis. First, healthcare

institutions should implement standardized, evidence-based risk assessment tools with

systematic documentation and monitoring. Second, comprehensive prophylaxis protocols

should be developed incorporating both mechanical and pharmacological interventions with

clear indications for each approach. Third, healthcare provider education programs should

address knowledge gaps in risk assessment and prophylaxis implementation. Fourth, quality

monitoring systems should be established to track both process measures and clinical

outcomes with regular feedback mechanisms.

Finally, future research should focus on comparative effectiveness of different

implementation strategies, patient engagement approaches, and adaptation of protocols to

diverse healthcare settings and populations. The ultimate goal of eliminating preventable

VTE-related maternal morbidity and mortality requires sustained commitment to evidence-

based practice improvement and quality monitoring.

The evidence clearly supports the efficacy of VTE prophylaxis following cesarean section.

The challenge lies in translating this evidence into consistent, high-quality clinical practice.

Through systematic attention to quality assessment and improvement, healthcare providers

can significantly reduce the burden of this preventable complication while optimizing

maternal safety and outcomes.

References

1. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018

guidelines for management of venous thromboembolism: venous thromboembolism in the

context

of

pregnancy.

Blood

Adv.

2018;2(22):3317-3359.

doi:10.1182/bloodadvances.2018024802


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

M

ay

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

2. Knight M, Tuffnell D, Kenyon S, et al. Saving Lives, Improving Mothers’ Care:

Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries

into Maternal Deaths and Morbidity 2014–16. MBRRACE-UK, 2018.

3. Sultan AA, West J, Grainge MJ, et al. Risk of first venous thromboembolism in and

around pregnancy: a population-based cohort study. BMJ. 2012;345:e6363.

doi:10.1136/bmj.e6363

4. ACOG Practice Bulletin No. 196. Thromboembolism in Pregnancy. Obstet Gynecol.

2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706

5. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in

over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary

embolism. NICE guideline [NG89]. 2018.

6. James AH. Prevention and management of thromboembolism in pregnancy. Am J Med.

2007;120(10 Suppl 2):S26-34. doi:10.1016/j.amjmed.2007.07.012

7. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period

and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb

Haemost. 2008;6(4):632-637. doi:10.1111/j.1538-7836.2008.02921.x

8. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE,

thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and

Prevention of Thrombosis. Chest. 2012;141(2_suppl):e691S-e736S.

9. RCOG Green-top Guideline No. 37a. Reducing the Risk of Venous Thromboembolism

during Pregnancy and the Puerperium. Royal College of Obstetricians and Gynaecologists,

2015.

10. Langen E, Streiff MB, Sachs BP, Bauersachs R, Heit JA. Venous thromboembolism in

women: current status and challenges. Lancet Haematol. 2021;8(3):e209-e220.

doi:10.1016/S2352-3026(20)30356-3

11. D'Alton ME, Friedman AM, Smiley RM, et al. National Partnership for Maternal Safety:

Consensus Bundle on Venous Thromboembolism. Obstet Gynecol. 2016;128(4):688-696.

doi:10.1097/AOG.0000000000001647

12. Lindqvist PG, Torsson J, Almqvist Y, Björgell O. Thromboprophylaxis use and risk

assessment in elective cesarean deliveries in Sweden: a national survey. Acta Obstet

Gynecol Scand. 2019;98(3):365-372. doi:10.1111/aogs.13500

13. Chan WS, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy

in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527-553. doi:10.1016/S1701-

2163(15)30500-6

14. Owens MY, Villarreal A, Shah A, et al. Evaluation of a risk-based thromboprophylaxis

protocol for cesarean deliveries: a cohort study. Am J Perinatol. 2018;35(4):354-359.

doi:10.1055/s-0037-1606355

15. Jacobson BF, Louw S, Büller H, et al. Venous thromboembolism: prophylactic and

therapeutic practice guideline. S Afr Med J. 2013;103(4 Pt 2):261-267.

doi:10.7196/SAMJ.6706

16. Ferres MA, Newman TB, Gao C, et al. Impact of a quality improvement bundle on

compliance with guidelines for prevention of venous thromboembolism in cesarean

deliveries.

J

Matern

Fetal

Neonatal

Med.

2021;34(19):3247-3252.

doi:10.1080/14767058.2019.1697546

References

Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802

Knight M, Tuffnell D, Kenyon S, et al. Saving Lives, Improving Mothers’ Care: Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2014–16. MBRRACE-UK, 2018.

Sultan AA, West J, Grainge MJ, et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. BMJ. 2012;345:e6363. doi:10.1136/bmj.e6363

ACOG Practice Bulletin No. 196. Thromboembolism in Pregnancy. Obstet Gynecol. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706

National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline [NG89]. 2018.

James AH. Prevention and management of thromboembolism in pregnancy. Am J Med. 2007;120(10 Suppl 2):S26-34. doi:10.1016/j.amjmed.2007.07.012

Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632-637. doi:10.1111/j.1538-7836.2008.02921.x

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis. Chest. 2012;141(2_suppl):e691S-e736S.

RCOG Green-top Guideline No. 37a. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Royal College of Obstetricians and Gynaecologists, 2015.

Langen E, Streiff MB, Sachs BP, Bauersachs R, Heit JA. Venous thromboembolism in women: current status and challenges. Lancet Haematol. 2021;8(3):e209-e220. doi:10.1016/S2352-3026(20)30356-3

D'Alton ME, Friedman AM, Smiley RM, et al. National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstet Gynecol. 2016;128(4):688-696. doi:10.1097/AOG.0000000000001647

Lindqvist PG, Torsson J, Almqvist Y, Björgell O. Thromboprophylaxis use and risk assessment in elective cesarean deliveries in Sweden: a national survey. Acta Obstet Gynecol Scand. 2019;98(3):365-372. doi:10.1111/aogs.13500

Chan WS, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527-553. doi:10.1016/S1701-2163(15)30500-6

Owens MY, Villarreal A, Shah A, et al. Evaluation of a risk-based thromboprophylaxis protocol for cesarean deliveries: a cohort study. Am J Perinatol. 2018;35(4):354-359. doi:10.1055/s-0037-1606355

Jacobson BF, Louw S, Büller H, et al. Venous thromboembolism: prophylactic and therapeutic practice guideline. S Afr Med J. 2013;103(4 Pt 2):261-267. doi:10.7196/SAMJ.6706

Ferres MA, Newman TB, Gao C, et al. Impact of a quality improvement bundle on compliance with guidelines for prevention of venous thromboembolism in cesarean deliveries. J Matern Fetal Neonatal Med. 2021;34(19):3247-3252. doi:10.1080/14767058.2019.1697546